1.            Rosenberg, N. et al. Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling. J. Hepatol. 77, 1631–1641 (2022).

2.            Paldor, M. et al. Single-cell transcriptomics reveals a senescence-associated IL-6/CCR6 axis driving radiodermatitis. EMBO Mol. Med. 14, (2022).

3.            Shriki, A. et al. Multiple roles of il6 in hepatic injury, steatosis, and senescence aggregate to suppress tumorigenesis. Cancer Res. 81, 4766–4777 (2021).

4.            Zuaiter, M., Axelrod, J. H., Pizov, G. & Gofrit, O. N. Hyper-Interleukin-6 Protects Against Renal Ischemic-Reperfusion Injury—A Mouse Model. Front. Surg. 8, (2021).

5.            Gamaev, L. et al. The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma. Oncogene 40, 127–139 (2021).

6.            Grand, M. et al. Hepatic Inflammation Confers Protective Immunity Against Liver Stages of Malaria Parasite. Front. Immunol. 11, (2020).

7.            Chai, C. et al. Agonist of RORA Attenuates Nonalcoholic Fatty Liver Progression in Mice via Up-regulation of MicroRNA 122. Gastroenterology 159, 999-1014.e9 (2020).

8.            Khatib, A. et al. The glutathione peroxidase 8 (GPX8)/IL-6/STAT3 axis is essential in maintaining an aggressive breast cancer phenotype. Proc. Natl. Acad. Sci. U. S. A. 117, 21420–21431 (2020).

9.            Durlacher-Betzer, K. et al. Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease. Kidney Int. 94, 315–325 (2018).

10.          Moll, J. M. et al. Split2 Protein-Ligation Generates Active IL-6-Type Hyper-Cytokines from Inactive Precursors. ACS Synth. Biol. 6, 2260–2272 (2017).

11.          Kleinschmidt, D. et al. A protective function of IL-22BP in ischemia reperfusion and acetaminophen-induced liver injury. J. Immunol. 199, 4078–4090 (2017).

12.          Lanton, T. et al. Interleukin 6–dependent genomic instability heralds accelerated carcinogenesis following liver regeneration on a background of chronic hepatitis. Hepatology 65, 1600–1611 (2017).

13.          Marmary, Y. et al. Radiation-induced loss of salivary gland function is driven by cellular senescence and prevented by IL6 modulation. Cancer Res. 76, 1170–1180 (2016).

14.          Zahavi, T. et al. Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model. Oncotarget 7, 4860–4870 (2016).

15.          Khamaisi, M. et al. Endothelin-converting enzyme is a plausible target gene for hypoxia-inducible factor. Kidney Int. 87, 761–770 (2015).

16.          Milman, Z., Axelrod, J. H., Heyman, S. N., Nachmansson, N. & Abramovitch, R. Assessment with unenhanced MRI techniques of renal morphology and hemodynamic changes during acute kidney injury and chronic kidney disease in mice. Am. J. Nephrol. 39, 268–278 (2014).

17.          Abu-Tair, L. et al. Natural killer cell-dependent anti-fibrotic pathway in liver injury via toll-like receptor-9. PLoS One 8, (2013).

18.          Barashi, N. et al. Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice. Hepatology 58, 1021–1030 (2013).

19.          Milman, Z. et al. Hemodynamic response magnetic resonance imaging: Application for renal hemodynamic characterization. Nephrol. Dial. Transplant. 28, 1150–1156 (2013).

20.          Sonnenblick, A. et al. Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer. Breast Cancer Res. Treat. 138, 407–413 (2013).

21.          Nechemia-Arbely, Y. et al. In vivo evidence suggesting reciprocal renal hypoxia-inducible factor-1 upregulation and signal transducer and activator of transcription 3 activation in response to hypoxic and non-hypoxic stimuli. Clin. Exp. Pharmacol. Physiol. 40, 262–272 (2013).

22.          Sonnenblick, A. et al. Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis. Clin. Transl. Oncol. 14, 232–236 (2012).

23.          Nechemia-Arbely, Y. et al. Early hepatocyte DNA synthetic response posthepatectomy is modulated by IL-6 trans-signaling and PI3K/AKT activation. J. Hepatol. 54, 922–929 (2011).

24.          Drenger, B. et al. Diabetes blockade of sevoflurane postconditioning is not restored by insulin in the rat heart: Phosphorylated signal transducer and activator of transcription 3- and phosphatidylinositol 3-kinase-mediated inhibition. Anesthesiology 114, 1364–1372 (2011).

25.          Nechemia-Arbely, Y. et al. IL-6/IL-6R axis plays a critical role in acute kidney injury. J. Am. Soc. Nephrol. 19, 1106–1115 (2008).

26.          Arad, U., Axelrod, J., Ben-nun-Shaul, O., Oppenheim, A. & Galun, E. Hepatitis B virus enhances transduction of human hepatocytes by SV40-based vectors. J. Hepatol. 40, 520–526 (2004).

27.          Sonza, S. et al. Selectively reduced tat mRNA heralds the decline in productive human immunodeficiency virus type 1 infection in monocyte-derived macrophages. J. Virol. 76, 12611–12621 (2002).

28.          Galun, E. & Axelrod, J. H. The role of cytokines in liver failure and regeneration: Potential new molecular therapies. Biochim. Biophys. Acta - Mol. Cell Res. 1592, 345–358 (2002).

29.          Hecht, N. et al. Hyper-IL-6 gene therapy reverses fulminant hepatic failure. Mol. Ther. 3, 683–687 (2001).

30.          Axelrod, J. H. & Honigman, A. A sensitive and versatile bioluminescence bioassay for HIV type 1 based on adenoviral vectors. AIDS Res. Hum. Retroviruses 15, 759–767 (1999).

31.          Baru, M., Axelrod, J. H. & Nur, I. Liposome-encapsulated DNA-mediated gene transfer and synthesis of human factor IX in mice. Gene 161, 143–150 (1995).

32.          Roman, M. et al. Circulating human or canine factor IX from retrovirally transduced primary myoblasts and established myoblast cell lines grafted into murine skeletal muscle. Somat. Cell Mol. Genet. 18, 247–258 (1992).

33.          Scharfmann, R., Axelrod, J. H. & Verma, I. M. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc. Natl. Acad. Sci. U. S. A. 88, 4626–4630 (1991).

34.          Axelrod, J. H., Read, M. S., Brinkhous, K. M. & Verma, I. M. Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs. Proc. Natl. Acad. Sci. U. S. A. 87, 5173–5177 (1990).

35.          MISKIN, R. et al. Human and murine urokinase cDNAs linked to the murine αA‐crystallin promoter exhibit lens and non‐lens expression in transgenic mice. Eur. J. Biochem. 190, 31–38 (1990).

36.          Axelrod, J. H., Reich, R. & Miskin, R. Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells. Mol. Cell. Biol. 9, 2133–2141 (1989).

37.          Rotem, N., Axelrod, J. H. & Miskin, R. Induction of urokinase-type plasminogen activator by UV light in human fetal fibroblasts is mediated through a UV-induced secreted protein. Mol. Cell. Biol. 7, 622–631 (1987).

38.          Rajput, B. et al. Chromosomal locations of human tissue plasminogen activator and urokinase genes. Science (80-. ). 230, 672–674 (1985).